However, this was discontinued, since a recent randomized phase III trial of patients with high-risk neuroblastoma showed that the addition of IL-2 to anti-GD2 antibody therapy did not improve outcome and increased treatment toxicity [8]. Here, IL2 is linked to neuroblastoma.